220 related articles for article (PubMed ID: 31724304)
21. Predictive Factor Analysis of Response-Adapted Radiation Therapy for Chemotherapy-Sensitive Pediatric Hodgkin Lymphoma: Analysis of the Children's Oncology Group AHOD 0031 Trial.
Charpentier AM; Friedman DL; Wolden S; Schwartz C; Gill B; Sykes J; Albert-Green A; Kelly KM; Constine LS; Hodgson DC
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):943-950. PubMed ID: 27869096
[TBL] [Abstract][Full Text] [Related]
22. Patterns of relapse from a phase 3 Study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the Children's Oncology Group.
Dharmarajan KV; Friedman DL; Schwartz CL; Chen L; FitzGerald TJ; McCarten KM; Kessel SK; Iandoli M; Constine LS; Wolden SL
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):60-6. PubMed ID: 25542311
[TBL] [Abstract][Full Text] [Related]
23. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.
Sasse S; Bröckelmann PJ; Goergen H; Plütschow A; Müller H; Kreissl S; Buerkle C; Borchmann S; Fuchs M; Borchmann P; Diehl V; Engert A
J Clin Oncol; 2017 Jun; 35(18):1999-2007. PubMed ID: 28418763
[TBL] [Abstract][Full Text] [Related]
24. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
[TBL] [Abstract][Full Text] [Related]
25. Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation.
Metzger ML; Link MP; Billett AL; Flerlage J; Lucas JT; Mandrell BN; Ehrhardt MJ; Bhakta N; Yock TI; Friedmann AM; de Alarcon P; Luna-Fineman S; Larsen E; Kaste SC; Shulkin B; Lu Z; Li C; Hiniker SM; Donaldson SS; Hudson MM; Krasin MJ
J Clin Oncol; 2021 Jul; 39(20):2276-2283. PubMed ID: 33826362
[TBL] [Abstract][Full Text] [Related]
26. Hodgkin Lymphoma in Adolescent and Young Adults: Real-World Data from a Single Tertiary Cancer Center in India.
Nayak L; Jain H; Bonda A; Epari S; Laskar S; Gokarn A; Shet T; Gujral S; Khanna N; Bagal B; Punatar S; Goda J; Thorat J; Rengaraj K; Sengar M
J Adolesc Young Adult Oncol; 2021 Oct; 10(5):581-587. PubMed ID: 33090916
[No Abstract] [Full Text] [Related]
27. Improved survival of children and adolescents with classical Hodgkin lymphoma treated on a harmonised protocol in South Africa.
Geel J; van Zyl A; Plessis JD; Hendricks M; Goga Y; Carr A; Neethling B; Hramyka A; Omar F; Mathew R; Louw L; Naidoo T; Ngcana T; Schickerling T; Netshituni V; Madzhia E; du Plessis L; Kelsey T; Ballot DE; Metzger ML
Pediatr Blood Cancer; 2024 Jan; 71(1):e30712. PubMed ID: 37814417
[TBL] [Abstract][Full Text] [Related]
28. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
Press OW; Li H; Schöder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; Mittra ES; LaCasce AS; Sweetenham JW; Barr PM; Fanale MA; Knopp MV; Noy A; Hsi ED; Cook JR; Lechowicz MJ; Gascoyne RD; Leonard JP; Kahl BS; Cheson BD; Fisher RI; Friedberg JW
J Clin Oncol; 2016 Jun; 34(17):2020-7. PubMed ID: 27069074
[TBL] [Abstract][Full Text] [Related]
29. Response assessment by positron emission tomography-computed tomography as compared with contrast-enhanced computed tomography in childhood Hodgkin lymphoma can reduce the need for radiotherapy in low- and middle-income countries.
Kalra M; Bakhshi S; Singh M; Seth R; Verma N; Jain S; Radhakrishnan V; Mandal P; Mahajan A; Arora RS; Dinand V; Kapoor G; Sajid M; Kumar R; Taluja A; Mallick S; Chandra J
Pediatr Blood Cancer; 2023 Feb; 70(2):e30091. PubMed ID: 36411263
[TBL] [Abstract][Full Text] [Related]
30. Hodgkin's disease in Indian children: outcome with chemotherapy alone.
Arya LS; Dinand V; Thavaraj V; Bakhshi S; Dawar R; Rath GK; Singh R; Vats TS
Pediatr Blood Cancer; 2006 Jan; 46(1):26-34. PubMed ID: 16161019
[TBL] [Abstract][Full Text] [Related]
31. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
Dann EJ; Bairey O; Bar-Shalom R; Mashiach T; Barzilai E; Kornberg A; Akria L; Tadmor T; Filanovsky K; Abadi U; Kagna O; Ruchlemer R; Abdah-Bortnyak R; Goldschmidt N; Epelbaum R; Horowitz NA; Lavie D; Ben-Yehuda D; Shpilberg O; Paltiel O
Br J Haematol; 2017 Sep; 178(5):709-718. PubMed ID: 28589704
[TBL] [Abstract][Full Text] [Related]
32. Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.
Iannitto E; Minardi V; Gobbi PG; Calvaruso G; Tripodo C; Marcheselli L; Luminari S; Merli F; Baldini L; Stelitano C; Callea V; Petrini M; Angrilli F; Quarta G; Vallisa D; Molica S; Liardo E; Polimeno G; Brugiatelli M; Federico M
Clin Lymphoma Myeloma; 2009 Apr; 9(2):138-44. PubMed ID: 19406724
[TBL] [Abstract][Full Text] [Related]
33. Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial.
Gallamini A; Tarella C; Viviani S; Rossi A; Patti C; Mulé A; Picardi M; Romano A; Cantonetti M; La Nasa G; Trentin L; Bolis S; Rapezzi D; Battistini R; Gottardi D; Gavarotti P; Corradini P; Cimminiello M; Schiavotto C; Parvis G; Zanotti R; Gini G; Ferreri AJM; Viero P; Miglino M; Billio A; Avigdor A; Biggi A; Fallanca F; Ficola U; Gregianin M; Chiaravalloti A; Prosperini G; Bergesio F; Chauvie S; Pavoni C; Gianni AM; Rambaldi A
J Clin Oncol; 2018 Feb; 36(5):454-462. PubMed ID: 29360414
[TBL] [Abstract][Full Text] [Related]
34. Twenty-year disease and treatment-associated mortality rates of patients with Hodgkin lymphoma of clinical stages IIIB and IV prospectively treated with 3-month anthracycline-based chemotherapy followed by extended high-dose radiation.
Sénécal D; Jais JP; Desablens B; Berthou C; Casassus P; Moles MP; Delwail V; Gastinne T; Colonna P; Andrieu JM
Cancer; 2008 Feb; 112(4):846-55. PubMed ID: 18072259
[TBL] [Abstract][Full Text] [Related]
35. Treatment of pediatric Hodgkin disease tailored to stage, mediastinal mass, and age. An Italian (AIEOP) multicenter study on 215 patients.
Vecchi V; Pileri S; Burnelli R; Bontempi N; Comelli A; Testi AM; Carli M; Sotti G; Rosati D; Di Tullio MT
Cancer; 1993 Sep; 72(6):2049-57. PubMed ID: 7689924
[TBL] [Abstract][Full Text] [Related]
36. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.
Kedmi M; Apel A; Davidson T; Levi I; Dann EJ; Polliack A; Ben-Bassat I; Nagler A; Avigdor A
Acta Haematol; 2016; 135(3):156-61. PubMed ID: 26588173
[TBL] [Abstract][Full Text] [Related]
37. Ten-year results of a strategy combining three cycles of ABVD and high-dose extended irradiation for treating Hodgkin's disease at advanced stages.
Andrieu JM; Jais JP; Colonna P; Desablens B; Brière J; François S; Harousseau JL; Casassus P; Lemevel A; Le Prisé PY; Ghandour C; Guilhot F; Lejeune F
Ann Oncol; 1998 Feb; 9(2):195-203. PubMed ID: 9553666
[TBL] [Abstract][Full Text] [Related]
38. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial.
Mounier N; Brice P; Bologna S; Briere J; Gaillard I; Heczko M; Gabarre J; Casasnovas O; Jaubert J; Colin P; Delmer A; Devidas A; Bachy E; Nicolas-Virelizier E; Aoudjhane A; Humbrecht C; Andre M; Carde P;
Ann Oncol; 2014 Aug; 25(8):1622-8. PubMed ID: 24827123
[TBL] [Abstract][Full Text] [Related]
39. Radiation therapy for early stage unfavorable Hodgkin lymphoma: is dose reduction feasible?
Laskar S; Kumar DP; Khanna N; Menon H; Sengar M; Arora B; Gujral S; Shet T; Sridhar E; Rangarajan V; Muckaden MA; Nair R; Banavali S
Leuk Lymphoma; 2014 Oct; 55(10):2356-61. PubMed ID: 24354681
[TBL] [Abstract][Full Text] [Related]
40. Treatment of childhood Hodgkin's disease with COPP or COPP-ABV (hybrid) without radiotherapy in Nicaragua.
Baez F; Ocampo E; Conter V; Flores A; Gutierrez T; Malta A; Pacheco C; Palacios R; Biondi A; Riva L; Sala A; Silvestri D; Cavalli F; Sessa C; Casanova M; Masera G
Ann Oncol; 1997 Mar; 8(3):247-50. PubMed ID: 9137793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
